Tivicay (dolutegravir) / ViiV Healthcare 
Welcome,         Profile    Billing    Logout  
 26 Diseases   58 Trials   58 Trials   4692 News 


«12...1819202122232425262728...6263»
  • ||||||||||  bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Reduction in the weight, gained due to dolutegravir, following switch to bictegravir. (Pubmed Central) -  Jul 20, 2022   
    Our finding could be the first instance were weight loss has been reported post switching the patients from DTG therapy to Bictegravir. Considering smaller patient population this outcome may need further confirmed through large group study.
  • ||||||||||  Review, Journal:  Approved HIV reverse transcriptase inhibitors in the past decade. (Pubmed Central) -  Jul 20, 2022   
    Novel RT inhibitors such as islatravir, MK-8504, MK-8507, MK8583, IQP-0528, and MIV-150 will be also highlighted. Future development may focus on the new generation of novel antiretroviral inhibitors with higher bioavailability, longer elimination half-life, more favorable side-effect profiles, fewer drug-drug interactions, and higher activities against circulating drug-resistant strains.
  • ||||||||||  metformin / Generic mfg.
    Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1868;    
    A recent addition of dulaglutide causing diarrhea combined with a night of binge drinking causing emesis sent this patient into dangerous metabolic acidosis. Without prompt intervention, lactic acidosis from toxic metformin levels could have been devastating.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Update on neural tube defects with antiretroviral exposure in the Tsepamo Study, Botswana () -  Jul 2, 2022 - Abstract #AIDS2022AIDS_3933;    
    In comparison, NTDs occurred in 25/23,664 (0.11%; 95%CI 0.07%, 0.16%) women on any non-DTG ARVs from conception, 11/14,432 (0.08%; 95%CI 0.04%, 0.14%) on efavirenz from conception, 4/6,551 (0.06%; 95%CI 0.02%, 0.16%) on dolutegravir started in pregnancy, and 108/170,723 (0.07%; 95%CI 0.05, 0.08%) among women without HIV. The prevalence of NTDs among infants born to women on DTG at conception has declined to 0.11% and does not substantially differ from other exposure groups.
  • ||||||||||  dolutegravir/emtricitabine/tenofovir alafenamide (DTG/FTC/TAF) / Mylan
    Final week 192 results from the ADVANCE trial: first-line TAF/FTC/DTG, TDF/FTC/DTG vs TDF/FTC/EFV () -  Jul 2, 2022 - Abstract #AIDS2022AIDS_3932;    
    In the ADVANCE trial, participants taking TAF/FTC+DTG experienced greater weight gain and clinical obesity than TDF/FTC/DTG by Week 192, particularly in women, but no significant differences in HIV RNA suppression or renal or bone-related adverse events. Both TAF/FTC/DTG and TDF/FTC/DTG had significantly higher rates of HIV RNA suppression than TDF/FTC/EFV at Week 192 in the main ITT analysis.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. (Pubmed Central) -  Jul 2, 2022   
    P4
    The results of this study emphasise the need for thorough screening for TB for patients being transitioned to DTG based therapy with recycled NRTI backbone and the need for prospective follow-up studies to establish utility of newer molecules such as Tenofovir Alafenamide/Emtricitabine/Dolutegravir with antituberculous therapy. Forty-eight weeks after switching from a PI-based to a dolutegravir-based regimen, patients with Framingham score >10% or aged >50 years showed improvement of several atherogenic lipid features, including LDL particle phenotype, ox-LDL and Lp-PLA2.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    PK/PD data, Journal:  Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin. (Pubmed Central) -  Jun 24, 2022   
    P1
    Although 50 mg of dolutegravir given twice daily achieves target concentrations in more than 99% of individuals cotreated with rifampicin, 100 mg of dolutegravir, once daily, in the same population is predicted to achieve satisfactory pharmacokinetic target attainment. The efficacy of this regimen should be investigated since it presents an opportunity for treatment simplification.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Trial completion date, Trial primary completion date:  D (clinicaltrials.gov) -  Jun 22, 2022   
    P3b/4,  N=813, Active, not recruiting, 
    Increased efforts must be made to address LTFU and to support under-fives and adolescents. Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Jul 2023
  • ||||||||||  Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    Retrospective data, Journal:  Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study. (Pubmed Central) -  Jun 22, 2022   
    In acquired immunodeficiency syndrome-diagnosed patients, we found a significant increase in the CD4+ T-cell count at week 48 (log OR = 41.7, P = .0038), but no significant changes in the CD8+ T-cell count (log OR = -23.4, P = .54). No differences were found in the CD4/CD8 ratio between the acquired immunodeficiency syndrome subgroup and sex or age.In patients with controlled treatment, dual therapy with DTG plus RPV slightly improved the immune status during the first 48 weeks after switching, not only in terms of CD4+ T-cell count but also in terms of CD8+ T-cell count, with persistently high rates of viral control.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    DTG associated weight gain: real or perceived? Real world experiences from Zimbabwe () -  Jun 19, 2022 - Abstract #AIDS2022AIDS_3310;    
    We compared real-world weight changes after starting or switching of treatment for DTG, efavirenz (EFV), and atazanavir (ATV/r) based regimens... Patients receiving DTG based regimens had a two- to four-fold weight gain compared to EFV and ATV/r over two years, with little evidence of plateauing of the trend among those in on DTG.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
    Safety outcomes among HIV-1 positive Zambian adults receiving Tenofovir Alafenamide combined with Dolutegravir: results from the VISEND clinical trial () -  Jun 19, 2022 - Abstract #AIDS2022AIDS_3274;    
    The VISEND trial is a 144 week, randomized, open label, phase 3 noninferiority study in which weenrolled HIV-1 positive Zambian adults individuals who were receiving TDF/lamivudine (3TC) /efavirenz (EFV) or nevirapine (NVP) ART. Individuals on TAF/FTC/DTG had better renal and bone safety profiles whereas pregnancy outcomes were comparable in both groups.TAFED was associated with increased weight gain.Tenofovir alafenamide offers a choice for an ARV with balancedoptimal efficacy and potential for improved long-term safety among HIV positive individuals on ART.However,long term follow up is needed to ascertain metabolic complications in women.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    SA061 The next frontier for HIV treatment optimization: Lessons from the past and visions for the future (Room 524/Channel 9) -  Jun 19, 2022 - Abstract #AIDS2022AIDS_3055;    
    Today over 90 percent of adults on first-line treatment are expected to be on dolutegravir (DTG)-based regimens, DTG is now available for the youngest children, and once-out-of-reach protease inhibitors are available at affordable prices...This satellite session will bring together key stakeholders to reflect on the innovative market interventions that have transformed the HIV treatment landscape in low- and middle-income countries and how these learnings will shape future initiatives. The session will challenge key stakeholders, including suppliers, national programs, and donors, to chart the future course of HIV treatment optimization and catalyze the rapid and appropriate introduction of next-generation innovations, including long-acting products.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation. (Pubmed Central) -  Jun 19, 2022   
    Each affect an extended NM2DTG apparent half-life recorded by PK parameters. The NM2DTG product can impact therapeutic adherence, tolerability, and access of a widely used integrase inhibitor in both resource limited and rich settings to reduce HIV-1 transmission and achieve optimal treatment outcomes.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal, Real-world evidence:  Adherence to and Forgiveness of 3TC/DTG in a Real-World Cohort. (Pubmed Central) -  Jun 14, 2022   
    A PDC lower than 80% was associated with a negative outcome irrespective of the HIV-RNA threshold considered. The extensive virologic efficacy of 3TC/DTG demonstrated both in clinical trials and real-world experiences seems to rely more on its friendliness than on its forgiveness.